Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Lutetium‐177‐dotatate ((177)Lu‐dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Zhu, Mojun, Bassam Sonbol, Mohamad, Halfdanarson, Thorvardur, Hobday, Timothy, Ahn, Daniel, Ma, Wen Wee, Bekaii‐Saab, Tanios
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Brief Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418337/
https://ncbi.nlm.nih.gov/pubmed/32510802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados